Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025

+ Include: 47 Videos (.mp4) + 47 Subtitles (.vtt) + 1 PDFs, size: 11.3 GB + Target Audience: surgical oncologists and hepatologists + Information:

1. Overview

The Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025 focuses on the latest innovations in managing metastatic colorectal cancer and pancreatic cancer. The course covers evolving surgical strategies, novel therapeutics, and emerging biomarkers for both resectable and unresectable disease. Course Dates: November 20–21, 2025

2. Learning Objectives

• Evaluate the role of hepatic arterial infusion (HAI) chemotherapy and systemic therapies in adjuvant and neoadjuvant settings.

• Debate surgical versus non-surgical approaches for resectable and unresectable liver metastases, including ablation and transplantation.

• Analyze the utility of circulating tumor DNA (ctDNA) and molecular profiling in prognosis and treatment selection.

• Discuss the integration of novel immunotherapies, vaccines, and targeted agents into HPB malignancy care.

• Implement multidisciplinary strategies for managing complex cases of early-onset colorectal cancer and pancreatic adenocarcinoma.

3. Target Audience

Best for surgical oncologists and hepatologists who want updates on HPB malignancies, advanced surgical techniques, and systemic therapies.

4. Topics

• Ablation vs Resection for Small Tumors

• Advanced Endoscopy

• Advanced PDAC

• ALPPS- Is There Still a Role

• Biomarkers, ctDNA

• Changing Demographics of Colorectal Cancer- Young Onset CRC

• Clinical Genomics, Screening

• Cysts and Interception

• Debate- Resectable PDAC – Surgery First vs. Neoadjuvant

• Defining Resectable Disease- Technical and Biologic Factors

• Diagnosis & Imaging – Panel Discussion and Q&A

• Emerging Role of Immunotherapy

• Epidemiology, Early Onset

• HAI Chemotherapy- Results in the Adjuvant Setting

• HAI FUDR — Updated Results and Conversion Systemic-Regional Therapy

• Histotripsy- What is the Real Benefit

• Homologous Repair Deficiency

• Imaging in Metastatic Colorectal Cancer- Diagnosis and Assessing Treatment Response

• Introduction – Panel Discussion and Q&A

• Is ctDNA a Helpful Prognostic Tool in Resectable Colorectal Cancer Liver Metastasis

• Liver Confined Disease- Updated Results of Resection

• Liver Resection with Extrahepatic Metastatic Disease- Yes or No

• Liver Transplantation- What is the Real Benefit

• Metastatic Disease — How Do I Treat

• MULTIDISCIPLINARY CASE PRESENTATIONS- Lesson from the Clinic

• Neoadjuvant Treatment for Pancreatic Cancer

• Novel Imaging, PET

• Novel Immunotherapies (Beyond Vaccines)

• Novel Therapeutics and Targeted Agents

• Novel Therapies & The Future – Panel Discussion and Q&A

• Pathology, Genomics, Testing

• RAS Biology and Treatment

• Resectable Liver Disease – Panel Discussion and Q&A

• Resectable PDAC

• Resectable, Borderline, & More – Panel Discussion and Q&A

• Robotic Technical Pearls (Liver, HAI)

• Role of Adjuvant-Neoadjuvant Systemic Therapy

• Role of EBRT

• Role of Molecular Profiling in Resectable Colorectal Cancer Liver Metastasis

• Selecting First-Line Systemic Therapy for Metastatic Colorectal Cancer in 2025

• Surgical Innovation, Prehab

• Synchronous Disease- Chemotherapy First vs. Resection First

• Systemic Therapies – Panel Discussion and Q&A

• Two-Stage Hepatic Resection

• Unresectable Liver Confined Disease – Panel Discussion and Q&A

• Vaccines- Personalized, Off the Shelf

• Y90 Radioembolization- Is There a Benefit